AXT indium phosphide supply and market growth

Overview

AXT has secured a long-term supply agreement with Lumentum Operations for indium phosphide wafer substrates, extending through 2031. The contract includes capacity reservations and is supported by $87.5 million in advance payments to be applied as credits toward future deliveries.

This agreement follows a period of growth for AXT, driven by demand for substrates used in AI infrastructure and optical connectivity. The company reported second-quarter revenue of $47.59 million, with the indium phosphide segment contributing $30.7 million. Following a rating upgrade from Zacks Research from ‘Hold’ to ‘Strong Buy’, AXT's stock has risen 451% since the beginning of the year.

More recently, AXTI, Inc. has experienced a significant breakout following a period of heavy institutional volume. After reaching a resistance level of $98.00, the stock has been testing support in the $70-$71 range. This surge is attributed to increased demand for Indium Phosphide in AI data centers.

Entities

AXT · CVD Equipment Corporation · Axsome Therapeutics · Zacks Research · Lumentum Operations

Timeline

1 day ago

[BUSINESS] 3 sources
Axsome Therapeutics, CVD Equipment, and AXTI show market activity
Axsome Therapeutics, CVD Equipment, and AXTI, Inc. report varying stock performance, driven by pharmaceutical growth, technical breakouts, and AI-related demand.
8 days ago

[BUSINESS] 2 sources
AXT secures long-term supply contract with Lumentum through 2031
AXT has signed a long-term supply deal with Lumentum Operations through 2031, backed by $87.5 million in advance payments to support growing demand for AI-related optical connectivity substrates.

Sources

ad-hoc-news.de · finanznachrichten.de · otravel.com · stocknews.com · tradingview.com

This summary has been updated 1 time: see revision history